Physician profile
Shrusan E Gray
NPI 1891951323
$2,600.43
in general payments reported to CMS, 2019-2025
25 companies · $255 in 2025
The $255 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $132 · 2021: $545 · 2022: $577 · 2023: $461 · 2024: $323 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $564.84 | 2019-2023 | |
| Hologic Sales and Service, LLC | $476.49 | 2019-2025 | Aptima, Acessa Provu System, Third Wave |
| Bayer Healthcare Pharmaceuticals INC. | $164.50 | 2019-2023 | |
| Mayne Pharma Commercial LLC | $163.62 | 2023-2024 | |
| Evofem Biosciences, INC. | $151.34 | 2020-2025 | Phexxi, Solosec, Phexx |
| Scynexis, INC. | $134.10 | 2022 | |
| Coopersurgical, INC. | $125.17 | 2021-2024 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $123.02 | 2024-2025 | Veozah |
| Pfizer INC. | $90.77 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $83.61 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $75.34 | 2021-2022 | |
| Allergan, INC. | $64.73 | 2019-2020 | |
| Therapeuticsmd, INC. | $58.51 | 2021 | |
| Avion Pharmaceuticals | $50.82 | 2021-2022 | |
| Lupin INC. | $47.06 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $38.50 | 2022-2023 | Nexplanon |
| Vertical Pharmaceuticals, LLC | $37.67 | 2019 | |
| Roche Diagnostics Corporation | $35.72 | 2019-2021 | |
| Millicent US INC | $24.61 | 2025 | Intrarosa |
| Meditrina | $17.28 | 2024 | |
| Convatec INC. | $16.05 | 2022 | |
| Amgen INC. | $16.01 | 2022 | |
| Ascend Therapeutics US, LLC | $14.00 | 2021 | |
| Shield Therapeutics INC | $13.66 | 2024 | |
| Exeltis, USA INC. | $13.01 | 2023 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shrusan Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.